No Data
No Data
No Data
No Data
No Data
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S (NYSE:NVO) after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and d
BenzingaApr 12 13:22 ET
Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target Is $48
Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48.
MT NewswiresApr 12 10:36 ET
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
TipRanksApr 12 01:41 ET
Express News | NYSE Order Imbalance 78033.0 Shares on Buy Side
Moomoo 24/7Apr 11 15:50 ET
Top 10 Best Performing S&P 500 Health Care Stocks of 2024
Seeking AlphaApr 10 14:56 ET
Novo Nordisk Parent Resubmits Application Seeking US Antirust Nod for Catalent Deal
Novo Nordisk (NOVO-B.CO) parent Novo Nordisk Foundation filed a new application to secure the US Federal Trade Commission's approval on its proposed acquisition of manufacturing subcontractor Catalent
MT NewswiresApr 9 00:05 ET
No Data
No Data